John A. Sedor, Chairman & CEO

John_Sedor_headshotJohn is a 30-year veteran of the pharmaceutical industry with a track record of creating value for shareholders at public and private companies.

Cangene: $220 million Sale of the Company
President, CEO, Board Member, Cangene Corporation (formerly TSX: CNJ) 2011 – 2014
Transformed Cangene from a biodefense developer/government contractor to a specialty pharmaceutical company
Divested non-core assets
Aligned manufacturing, marketing, and sales force across North America
Acquired Hemophelia assets from Ipsen
Acquired by Emergent BioSolutions in 2014 for $220 million, a 45% premium

Bentley: $375 million Sale of the Company
President, CEO, Bentley Pharmaceuticals (formerly NYSE: BNT) 2005-2008
Expanded nanotechnology programs, lead the launch of more than 20 new product in the EU
Acquired by Teva Pharmaceutical Industries in 2008 for $375 million

CPEX: $75 million Sale of the Company
Chief Executive Officer, President and Director, CPEX Pharmaceuticals (formerly NASDAQ: CPEX) 2009-2011
Orchestrated the spin-off of CPEX from Bentley as part of the transaction with Teva
Led development/commercialization of patented drug delivery technology
Sold to Footstar in 2011 for $75 million

Sandoz (division of Novartis AG): Increased U.S. Sales to $1.2 Billion
President, Sandoz Inc. 2001–2005
Led efforts to more than double net sales growth and overall profitability

Previously, Mr. Sedor served as President and Chief Executive Officer at Centeon, LLC, a joint venture between two major multinational corporations, Rhône-Poulenc Rorer and Hoechst AG. Previously, Mr. Sedor served as Executive Vice President at Rhône-Poulenc Rorer, Revlon Health Care and Parke-Davis. Mr. Sedor holds a Bachelor of Science degree in Pharmacy/Chemistry from Duquesne University, and has studied strategic marketing at both Northwestern University’s Kellogg Graduate School of Management and Harvard Business School. He has also attended Harvard’s Executive Forum.

Currently, Mr. Sedor is a Board Member, Pernix Therapeutics (NASDAQ: PTX), a specialty pharmaceutical company primarily focused on the sales, marketing, and development of branded pharmaceutical products. He also serves on the Board of Directors for Velico Medical Inc, a private medical technology company focused on applying proprietary technologies to improve the quality, a private medical technology company focused on applying proprietary technologies to improve the quality, availability and economics of plasma and platelet transfusions.